Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and the like has, predictably, returned. As always, we are coping by quaffing cups of stimulation. Our choice today is cherry chocolate decadence and, of course, you are invited to join us. Remember, no prescription is so required. And so, on to another busy day. On that note, here are some tidbits. We hope your journey goes well today and, by all means, do keep in touch …

Department of Health and Human Services Secretary Alex Azar is scheduled to give a speech on Monday afternoon to address drug pricing reforms and, in particular, is expected to announce the Trump administration will require drug makers to disclose list prices in consumer ads, Politico writes. The idea has generated controversy and the pharmaceutical industry trade group, meanwhile, plans to announce its own plans for consumer ads on Monday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.